3b blackbio dx Limited has announced its successful participation at MEDLAB Dubai and rescheduled its shareholder call to February 21st, 2026, according to a letter from Chairman and Managing Director Dhirendra Dubey dated February 19, 2026.

MEDLAB Dubai Participation Highlights

The company participated in MEDLAB Dubai from February 9-14, 2026, which proved to be a significant milestone for brand recognition. During the event, the management team engaged extensively with global companies and discovered that multiple international firms had heard of their TRUPCR and 3B brands.

Global Brand Recognition Achievement

The CEO emphasized that achieving global brand recognition represents a major milestone for the company. This recognition was attributed to the collective efforts of team members, partners, and stakeholders. The company's customer-centric approach, combined with quality products, fast supply, and technical support, has contributed to this industry acknowledgment.

A notable incident occurred when a foreign competitor acknowledged that "3B is giving us a tough time," while a respected industry senior praised the company's performance upon meeting them for the first time.

Partner Success and Business Opportunities

Coris, the company's partner, also participated with a booth adjacent to 3B BlackBio Dx. The event generated significant business opportunities for Coris, particularly given that Antimicrobial Resistance (AMR) was the main theme of the event. Coris showcased their globally recognized RESIST-5 brand, which aligns with their AMR expertise.

Shareholder Call Rescheduling

The originally scheduled shareholder call for February 18th has been postponed to February 21st, 2026, due to the CEO's health condition (laryngitis). The CEO explained that the intensive participation at MEDLAB Dubai, involving approximately 13,000 daily steps while exploring technologies and companies, likely contributed to his current health situation.

Industry Feedback and Future Outlook

The participation received positive feedback from various stakeholders, including Indian laboratory representatives who visit such events to explore new technologies and companies. The CEO noted that the company's presence instilled confidence among visitors about their capabilities and market position.

Distributors from multiple countries appreciated the company's approach and performance during the event. The management emphasized the importance of continuing their current strategies while maintaining vigilance against complacency in their operations.

3B BlackBio Dx Limited (formerly Kilpest India Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing robust performance across both standalone and consolidated operations. The Board of Directors approved these results at their meeting held on February 6, 2026.

Consolidated Financial Performance

The company delivered impressive consolidated results for Q3FY26, with significant growth across key financial metrics. The diagnostic kits segment emerged as a major growth driver, contributing substantially to the overall performance.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the consolidated performance showed consistent growth momentum across all major parameters.

Standalone Financial Results

The standalone operations also demonstrated solid performance, with revenue from operations reaching ₹2437.62 lakhs in Q3FY26 compared to ₹2343.00 lakhs in the corresponding previous quarter. Net profit for the standalone entity stood at ₹1446.02 lakhs versus ₹1344.84 lakhs in Q3FY25.

Segment-wise Performance

The company operates through two identified reportable business segments: Agrochemicals and Molecular Diagnostic Kits (Health Care Sector). The diagnostic kits segment showed remarkable performance with revenue of ₹4867.50 lakhs in Q3FY26 compared to ₹2328.30 lakhs in Q3FY25. The agrochemicals segment generated revenue of ₹167.23 lakhs during the quarter.

CORIS Acquisition Impact

The consolidated financials for Q3FY26 include CORIS sales of ₹2400.70 lakhs and profit of ₹700.10 lakhs. For the nine-month period, CORIS contributed sales of ₹2765.74 lakhs and profit of ₹658.20 lakhs, significantly enhancing the company's diagnostic capabilities and market presence.

Key Financial Highlights

Expense Management:

• Cost of materials consumed: ₹1367.34 lakhs (consolidated) vs ₹615.98 lakhs in Q3FY25
• Employee benefits expense: ₹821.31 lakhs vs ₹170.98 lakhs in previous year
• Other expenses included CE IVDR regulatory expenses and conference expenses

Balance Sheet Strength:

• Paid-up equity share capital: ₹856.84 lakhs
• Total segment assets: ₹41261.25 lakhs
• Capital employed: ₹35831.57 lakhs

Business Notes and Outlook

The company's agrochemical business remains seasonal in nature, with performance impacted by weather conditions and cropping patterns. The management noted that other expenses for the nine months included M&A expenses of ₹138.60 lakhs (₹84.06 lakhs in Q1 and ₹54.54 lakhs in Q2).

The company has evaluated the impact of new labour codes that became effective from November 21, 2025, determining that the impact on standalone financial results is not material. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by Baheti & Co., Chartered Accountants.